Citations to this article
Abstract
BACKGROUND Paclitaxel chemotherapy frequently induces dose-limiting sensory axonal polyneuropathy. Given that sensory symptoms are challenging to assess objectively in clinical practice, an easily accessible biomarker for chemotherapy-induced polyneuropathy (CIPN) holds the potential to improve early diagnosis. Here, we describe neurofilament light chain (NFL), a marker for neuroaxonal damage, as a translational surrogate marker for CIPN.METHODS NFL concentrations were measured in an in vitro model of CIPN, exposing induced pluripotent stem cell–derived sensory neurons (iPSC-DSNs) to paclitaxel. Patients with breast or ovarian cancer undergoing paclitaxel chemotherapy, breast cancer control patients without chemotherapy, and healthy controls were recruited in a cohort study and examined before chemotherapy (V1) and after 28 weeks (V2, after chemotherapy). CIPN was assessed by the validated Total Neuropathy Score reduced (TNSr), which combines patient-reported symptoms with data from clinical examinations. Serum NFL (NFLs) concentrations were measured at both visits with single-molecule array technology.RESULTS NFL was released from iPSC-DSNs upon paclitaxel incubation in a dose- and time-dependent manner and was inversely correlated with iPSC-DSN viability. NFLs strongly increased in paclitaxel-treated patients with CIPN, but not in patients receiving chemotherapy without CIPN or controls, resulting in an 86% sensitivity and 87% specificity. An NFLs increase of +36 pg/mL from baseline was associated with a predicted CIPN probability of more than 0.5.CONCLUSION NFLs was correlated with CIPN development and severity, which may guide neurotoxic chemotherapy in the future.TRIAL REGISTRATION ClinicalTrials.gov NCT02753036.FUNDING Deutsche Forschungsgemeinschaft (EXC 257 NeuroCure), BMBF (Center for Stroke Research Berlin, 01 EO 0801), Animalfree Research, EU Horizon 2020 Innovative Medicines Initiative 2 Joint Undertaking (TransBioLine, 821283), Charité 3R — Replace — Reduce — Refine.
Authors
Petra Huehnchen, Christian Schinke, Nikola Bangemann, Adam D. Dordevic, Johannes Kern, Smilla K. Maierhof, Lois Hew, Luca Nolte, Peter Körtvelyessy, Jens C. Göpfert, Klemens Ruprecht, Christopher J. Somps, Jens-Uwe Blohmer, Jalid Sehouli, Matthias Endres, Wolfgang Boehmerle
Citation information
Citations to this article (46)
| Title and authors | Publication | Year |
|---|---|---|
|
Biochemical use of neurofilament light polypeptide and vitamin B12 in relation to diabetic polyneuropathy in Danish adolescents with type 1 diabetes: a cross-sectional study
Thrysøe M, Parkner T, Tankisi H, Nyengaard JR, Vestergaard ET, Kristensen K, Terkelsen AJ, Rasmussen VF |
BMJ Open | 2025 |
|
Neurofilaments as Prognostic Biomarkers in the Assessment of the Risk of Advanced Taxane-Induced Neuropathy in Breast Cancer Patients—A Pilot Study
Makówka A, Fuksiewicz M, Bałata A, Borowiec A, Pogoda K, Nowecki Z, Jagiello-Gruszfeld A, Janas B, Kotowicz B |
Cancers | 2025 |
|
Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy
Gehr NL, Mortensen C, Stage TB, Pedersen MR, Rafaelsen SR, Madsen JS, Olsen DA, Timm S, Jensen LH, Hansen TF, Finnerup NB, Ventzel L |
Cancer Chemotherapy and Pharmacology | 2025 |
|
The Role of Microcirculatory Dysfunction During Paclitaxel Treatment as a Critical Co-Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy
Reuter S, Bajorat R, Müller-Graf F, Zitzmann AR, Müller V, Pickhardt AL, Reuter DA, Böhm SH, Vollmar B |
Geburtshilfe und Frauenheilkunde | 2025 |
|
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern.
Lanz TA, Ruprecht K, Somps CJ, Göpfert JC, Kam-Thong T, Tekle F, Fader KA, Yañez VAC, Meyer V, Friedrich S, Vlasakova K, Otto C, Paciga SA, Samodelov SL, Ramaiah SK |
Journal of neurology | 2025 |
|
The Kinetics of Microcirculatory Dysfunction During Paclitaxel Application in an In Vivo Mouse Model
Reuter S, Bajorat R, Müller-Graf F, Zitzmann AR, Böhm SH, Reuter DA, Vollmar B |
Journal of Clinical Medicine | 2025 |
|
Cognitive Implications of White Matter Alterations in Overweight Chinese Individuals: An NODDI and DTI Study.
Jiang S, Cheng Y, Jiang R, Huang P, Zhang J, Pan X, Xue Y |
Brain and behavior | 2025 |
|
Machine learning and biological validation identify sphingolipids as key mediators of paclitaxel-induced neuropathy in cancer patients
Jörn Lötsch, Khayal Gasimli, Sebastian Malkusch, Lisa Hahnefeld, Carlo Angioni, Yannick Schreiber, Sandra Trautmann, Saskia Wedel, Dominique Thomas, Nerea Bouzas, Christian Brandts, Benjamin Schnappauf, Christine Solbach, Gerd Geisslinger, Marco Sisignano |
eLife | 2024 |
|
Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)
Gehr NL, Karlsson P, Timm S, Christensen S, Hvid CA, Peric J, Hansen TF, Lauritzen L, Finnerup NB, Ventzel L |
BMC Cancer | 2024 |
|
Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury
Vlasakova K, Tsuchiya T, Garfinkel IN, Ruth MP, Tyszkiewicz C, Detwiler TJ, Somps CJ, Di Cesare Mannelli L, Glaab WE |
Frontiers in neuroscience | 2024 |
|
Neurofilaments as biomarkers in neurological disorders - towards clinical application.
Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, Bittner S, Sormani MP, Gattringer T, Abu-Rumeileh S, Thebault S, Abdelhak A, Green A, Benkert P, Kappos L, Comabella M, Tumani H, Freedman MS, Petzold A, Blennow K, Zetterberg H, Leppert D, Kuhle J |
Nature reviews. Neurology | 2024 |
|
An increase in ER stress and unfolded protein response in iPSCs-derived neuronal cells from neuronopathic Gaucher disease patients
Pornsukjantra T, Saikachain N, Sutjarit N, Khongkrapan A, Tubsuwan A, Bhukhai K, Tim-Aroon T, Anurathapan U, Hongeng S, Asavapanumas N |
Scientific Reports | 2024 |
|
Neurofilament Biophysics: From Structure to Biomechanics
Ding EA, Kumar S |
Molecular biology of the cell | 2024 |
|
Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathy.
Baka P, Steenken L, Escolano-Lozano F, Steffen F, Papagianni A, Sommer C, Pogatzki-Zahn E, Hirsch S, Protopapa M, Bittner S, Birklein F |
European Journal of Neurology | 2024 |
|
Plasma neurofilament light chain levels in chemotherapy‐induced peripheral neurotoxicity according to type of anticancer drug
Velasco R, Marco C, Domingo\u2010Domenech E, Stradella A, Santos C, Laquente B, Ferrer G, Argyriou AA, Bruna J |
European Journal of Neurology | 2024 |
|
Neurofilament light chain in serum of cancer patients with acute neurological complications.
Gottiparthy A, Lam K, Kundu S, Yang Z, Tremont-Lukats I, Tummala S |
CNS Oncology | 2024 |
|
Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy
Adra J, Giglio D, Karlsson P, Zetterberg H, Einbeigi Z |
Acta Oncologica | 2024 |
|
Chemotherapy-induced peripheral neuropathy models constructed from human induced pluripotent stem cells and directly converted cells: a systematic review
Smulders PS, Heikamp K, Hermanides J, Hollmann MW, ten Hoope W, Weber NC |
Pain | 2024 |
|
Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity
Cantor EL, Shen F, Jiang G, Philips S, Schneider BP |
Scientific Reports | 2024 |
|
3R centres contributions to change animal experimentation : A field report from Charité 3(R), the 3R centre of a medical faculty.
Retter I, Behm L, Grohmann L, Schmelz K, Rosowski J, Hippenstiel S |
EMBO reports | 2024 |
|
Characterization of Novel SARM1 Inhibitors for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chen J, Li H |
Biomedicines | 2024 |
|
Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study
Kerkmann A, Schinke C, Dordevic A, Kern J, Bangemann N, Finck J, Blohmer JU, Ruprecht K, Göpfert JC, Otto C, Materne B, Endres M, Boehmerle W, Huehnchen P |
The Oncologist | 2024 |
|
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives
Zhang J, Campion S, Catlin N, Reagan WJ, Palyada K, Ramaiah SK, Ramanathan R |
Archives of Toxicology | 2023 |
|
Systemic inflammatory markers in patients with polyneuropathies
García-Fernández P, Höfflin K, Rausch A, Strommer K, Neumann A, Cebulla N, Reinhold AK, Rittner H, Üçeyler N, Sommer C |
Frontiers in immunology | 2023 |
|
Sciatic nerve fractional anisotropy and neurofilament light chain protein are related to sensorimotor deficit of the upper and lower limbs in patients with type 2 diabetes
Kender Z, Jende JM, Kurz FT, Tsilingiris D, Schimpfle L, Sulaj A, von Rauchhaupt E, Bartl H, Mooshage C, Göpfert J, Nawroth P, Herzig S, Szendroedi J, Bendszus M, Kopf S |
Frontiers in Endocrinology | 2023 |
|
Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment
Tonyan S, Pospelova M, Krasnikova V, Fionik O, Alekseeva T, Samochernykh K, Ivanova N, Vavilova T, Vasilieva E, Makhanova A, Nikolaeva A, Bukkieva T, Combs S, Shevtsov M |
Pathophysiology | 2023 |
|
Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment
Cebulla N, Schirmer D, Runau E, Flamm L, Gommersbach S, Stengel H, Zhou X, Einsele H, Reinhold AK, Rogalla von Bieberstein B, Zeller D, Rittner H, Kortüm KM, Sommer C |
Journal of Neurology | 2023 |
|
Higher Levels of Cerebrospinal Fluid and Plasma Neurofilament Light in Human Immunodeficiency Virus-Associated Distal Sensory Polyneuropathy.
Ellis RJ, Chenna A, Lie Y, Curanovic D, Winslow J, Tang B, Marra CM, Rubin LH, Clifford DB, McCutchan JA, Gelman BB, Robinson-Papp J, Petropoulos CJ, Letendre SL |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023 |
|
Neurofilament Light Chain in Spinal Fluid and Plasma in Multiple System Atrophy - A Prospective, Longitudinal Biomarker Study.
Singer W, Schmeichel AM, Sletten DM, Gehrking TL, Gehrking JA, Trejo-Lopez J, Suarez MD, Anderson JK, Bass PH, Lesnick TG, Low PA |
Research square | 2023 |
|
Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
Singer W, Schmeichel AM, Sletten DM, Gehrking TL, Gehrking JA, Trejo-Lopez J, Suarez MD, Anderson JK, Bass PH, Lesnick TG, Low PA |
Clinical autonomic research : official journal of the Clinical Autonomic Research Society | 2023 |
|
Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy.
Cavaletti G, Pizzamiglio C, Man A, Engber TM, Comi C, Wilbraham D |
Cancers | 2023 |
|
Serum neurofilament light chain in COVID-19 and the influence of renal function
Körtvelyessy P, Diekämper E, Ruprecht K, Endres M, Stubbemann P, Kurth F, Graw JA, Menk M, Kuhle J, Wohlrab F |
European Journal of Medical Research | 2023 |
|
Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy
Lucarini E, Micheli L, Rajagopalan R, Ciampi C, Branca JJ, Pacini A, Leandri M, Rajagopalan P, Ghelardini C, Di Cesare Mannelli L |
PAIN | 2023 |
|
Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine
Balayssac D, Durif J, Lambert C, Dalbos C, Chapuy E, Etienne M, Demiot C, Busserolles J, Martin V, Sapin V |
Toxics | 2023 |
|
A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusion.
Corderfeldt Keiller A, Axelsson M, Bragadottir G, Blennow K, Zetterberg H, Olofsson Bagge R |
Perfusion | 2023 |
|
Circulating neurofilament light chain as a promising biomarker of AAV-induced dorsal root ganglia toxicity in nonclinical toxicology species
K Fader, I Pardo, R Kovi, C Somps, H Wang, V Vaidya, S Ramaiah, M Sirivelu |
Molecular Therapy — Methods & Clinical Development | 2022 |
|
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial
Huehnchen P, Bangemann N, Lischewski S, Märschenz S, Paul F, Schmitz-Hübsch T, Blohmer JU, Eberhardt C, Rauch G, Flöel A, Adam S, Schwenkenbecher P, Meinhold-Heerlein I, Hoffmann O, Ziemssen T, Endres M, Boehmerle W |
Frontiers in Medicine | 2022 |
|
Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria.
Alberti P, Semperboni S, Cavaletti G, Scuteri A |
Cells | 2022 |
|
Bridging the Translational Gap in Chemotherapy-Induced Peripheral Neuropathy with iPSC-Based Modeling.
Mortensen C, Andersen NE, Stage TB |
Cancers | 2022 |
|
Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.
Velasco R, Argyriou AA, Marco C, Mariotto S, Stradella A, Hernández J, Pernas S, Ferrari S, Bruna J |
Journal of Neurology | 2022 |
|
Induced pluripotent stem cell-derived brain organoids as potential human model system for chemotherapy induced CNS toxicity
Scholz S, Lewis K, Saulich F, Endres M, Boehmerle W, Huehnchen P |
Frontiers in Molecular Biosciences | 2022 |
|
Neurofilaments contribution in clinic: state of the art
Delaby C, Bousiges O, Bouvier D, Fillée C, Fourier A, Mondésert E, Nezry N, Omar S, Quadrio I, Rucheton B, Schraen-Maschke S, van Pesch V, Vicca S, Lehmann S, Bedel A |
Frontiers in aging neuroscience | 2022 |
|
Neurological Complications of Conventional and Novel Anticancer Treatments
Alberti P, Salvalaggio A, Argyriou AA, Bruna J, Visentin A, Cavaletti G, Briani C |
Cancers | 2022 |
|
The 2022 Lady Estelle Wolfson lectureship on neurofilaments
Petzold A |
Journal of Neurochemistry | 2022 |
|
Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
Maalmi H, Strom A, Petrera A, Hauck SM, Strassburger K, Kuss O, Zaharia OP, Bönhof GJ, Rathmann W, Trenkamp S, Burkart V, Szendroedi J, Ziegler D, Roden M, Herder C |
Diabetologia | 2022 |
|
GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu Q\u201C, Park JR, Gardner RA, Annesley CE |
Blood Advances | 2022 |
